Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome

This study examined the effects of pemafibrate, a selective peroxisome proliferator-activated receptor α agonist, on the serum biochemical parameters of male patients with coronary artery disease and metabolic syndrome (MetS). This was a post hoc analysis of a randomized, crossover study that treate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Heart and vessels 2024-06, Vol.39 (6), p.486-495
Hauptverfasser:	Nakamura, Akihiro, Kagaya, Yuta, Saito, Hiroki, Kanazawa, Masanori, Sato, Kenjiro, Miura, Masanobu, Kondo, Masateru, Endo, Hideaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alanine Alanine transaminase Benzoxazoles - pharmacology Benzoxazoles - therapeutic use Bezafibrate Bezafibrate - pharmacology Bezafibrate - therapeutic use Biomarkers - blood Biomedical Engineering and Bioengineering Butyrates - pharmacology Butyrates - therapeutic use Cardiac Surgery Cardiology Cardiovascular disease Coronary artery disease Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Coronary vessels Cross-Over Studies Heart diseases Homeostasis Humans Hypertriglyceridemia Hypertriglyceridemia - blood Hypertriglyceridemia - complications Hypertriglyceridemia - diagnosis Hypertriglyceridemia - drug therapy Hypolipidemic Agents - pharmacology Hypolipidemic Agents - therapeutic use Insulin Insulin Resistance Lipids Liver Male Males Medicine Medicine & Public Health Metabolic disorders Metabolic syndrome Metabolic Syndrome - blood Metabolic Syndrome - complications Metabolic Syndrome - diagnosis Metabolic Syndrome - drug therapy Middle Aged Original Article Parameters Peroxisome proliferator-activated receptors PPAR alpha - agonists Treatment Outcome Triglycerides Triglycerides - blood Vascular Surgery Vein & artery diseases γ-Glutamyltransferase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!